The agency's approval of the first seasonal flu vaccine made of recombinant proteins rather than inactivated or weakened virus comes as emergency rooms are clogged with victims of an early and severe flu season...
Congress's decision on January 1 to delay mandatory cuts to agencies, including the NIH and NSF, means administrators must still plan for possible plunges in funding for medical schools and other campuses...
The drug industry says the antibiotic pipeline is blocked by overly stringent clinical-trial requirements for new treatments
Critics say controversy over publication of mutant-H5N1 research highlights biosecurity weaknesses
Already a subscriber? Sign in.
